Last reviewed · How we verify
CCI18781
CCI18781 is a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R) that reduces macrophage proliferation and activation in the tumor microenvironment.
CCI18781 is a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R) that reduces macrophage proliferation and activation in the tumor microenvironment. Used for Advanced solid tumors (in combination with checkpoint inhibitors).
At a glance
| Generic name | CCI18781 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | CSF1R inhibitor |
| Target | CSF1R (Colony-Stimulating Factor 1 Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CSF1R inhibition decreases the recruitment and polarization of tumor-associated macrophages (TAMs), which are immunosuppressive cells that promote tumor growth and metastasis. By depleting or reprogramming these macrophages, CCI18781 aims to enhance anti-tumor immunity and improve the efficacy of checkpoint inhibitors or other immunotherapies.
Approved indications
- Advanced solid tumors (in combination with checkpoint inhibitors)
Common side effects
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 Years
- Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies. (PHASE4)
- Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |